DUBLIN – There are 98 antibody-drug conjugate (ADC) monotherapy development programs currently in the clinic, in addition to the four products already on the market, Steve Coats, vice president of R&D at the Medimmune arm of London-based Astrazeneca plc, told the audience at a workshop session on ADC warheads at the 30th annual EORTC-NCI-AACR meeting Wednesday. "They're probably not the magic bullets we had anticipated," he admitted. Nevertheless, interest in those agents remains high because of their ability to elicit responses in highly refractory cancer patients.